Context Therapeutics (NASDAQ:CNTX) Given "Buy" Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Context Therapeutics' Q3 2025 earnings at ($0.05) EPS and Q4 2025 earnings at ($0.05) EPS.

Several other brokerages have also issued reports on CNTX. JMP Securities started coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price on the stock. Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Wednesday, January 15th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $6.17.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX traded down $0.01 during midday trading on Friday, reaching $0.76. The company's stock had a trading volume of 33,761 shares, compared to its average volume of 388,443. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75. The firm has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $1.43. The firm has a market capitalization of $57.06 million, a price-to-earnings ratio of -0.84 and a beta of 2.06.

Remove Ads

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. As a group, research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds have recently bought and sold shares of CNTX. State Street Corp lifted its position in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after purchasing an additional 19,800 shares in the last quarter. Clear Harbor Asset Management LLC lifted its position in shares of Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after buying an additional 21,804 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $31,000. Finally, Millennium Management LLC grew its holdings in shares of Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after acquiring an additional 34,835 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.